231P The efficacy of adjuvant EGFR-TKI therapy for stage IA non-small cell lung cancer with EGFR mutations: A retrospective cohort study

Background: Pathologic complete response (pCR) is utilized more frequently as an endpoint in neoadjuvant immunotherapy trials for resectable non-small cell lung cancer (NSCLC).Its utility as a surrogate for long-term survival, however, remains debated.We conducted a systematic review to evaluate the association between pCR and survival outcomes in this setting. Methods:We performed a systematic search of PubMed, Embase and Cochrane Library, according to PRISMA guidelines.We included prospective